NR3C2 and myeloid sarcoma: In MS specifically, we propose collecting longitudinal data from larger groups on various disease-modifying treatments to corroborate the role of MR signaling in the clinical course; having identified an MR marker gene in peripheral blood will facilitate such an analysis.